Positive Phase II/III data for leniolisib have been presented at the annual congress of the Clinical Immunology Society (CIS).
Developed by Dutch rare disease specialist Pharming (Euronext: PHARM), the candidate is under development for activated phosphoinositide 3-kinase δ syndrome (APDS), a primary immunodeficiency affecting around one to two people per million.
Given that symptoms overlap with other conditions, the rare and progressive disorder is hard to diagnose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze